Diagnosing Dx

This week I’m joined by Yana Aznavour, MD, PhD, OB-GYN surgeon and Founder & CEO of Endometrics. We unpack one of the biggest failures in modern healthcare: why women are still waiting up to 11 years for an endometriosis diagnosis, why the current standard still relies on surgery, and what it takes to build a diagnostic that clinicians will actually trust and use. This conversation goes beyond...

In this episode of Diagnosing Dx, I’m joined by Maria Zannes, Chief Executive Officer and Director at bioAffinity Technologies. Maria shares her journey from journalism and business leadership into diagnostics, and explains how bioAffinity Technologies is building a non-invasive platform for lung disease diagnosis, starting with early lung cancer detection. We explore the limitations of current pa...

In this episode of Diagnosing Dx, I’m joined by ⁠ Garreth Hippe ⁠, Chief Commercial Officer at ⁠GenomOncology ⁠, a software company helping turn complex genomic data into faster, more actionable decisions in oncology. Garreth has spent much of his career in clinical genomics, bioinformatics, and healthcare software, and in this conversation we explore how the field has evolved over the last 20 yea...

In this first episode of Diagnosing WDx, the new women’s health-focused sister series from Diagnosing Dx, I’m joined by Marra Francis, MD , board-certified OB-GYN, women’s health expert, and advisor to multiple early-stage diagnostics companies. Recorded in the week of International Women’s Day, this conversation explores one of the biggest blind spots in healthcare: the historic and ongoing gap i...

In this episode of Diagnosing Dx, I’m joined by ⁠ Tammy Crawford⁠ , Chief Executive Officer, and ⁠ Holly Ahern ⁠, Chief Scientific Officer at ⁠ Aces Diagnostics ⁠, a company building what could become the first highly accurate test across all stages of Lyme disease. We explore why early Lyme is so often missed, the myth of the bullseye rash, and the structural gaps in today’s testing pathway. Tamm...

In this episode of Diagnosing Dx, I’m joined by ⁠ Spencer Price ⁠, Chief Executive Officer at ⁠ OraLiva ⁠, a company building an AI-powered precision diagnostic designed to transform oral cancer detection and shift the standard of care. We explore Spencer’s unconventional move from autonomous vehicles into diagnostics, why OraLiva built commercialisation and reimbursement strategy into the company...

In this episode of Diagnosing Dx, I’m joined by Jake Lesinski , Co-founder and CEO of Checktor Biosciences , an ETH Zurich spin-out building a CRISPR-based chemistry platform designed to upgrade existing diagnostic systems rather than replace them. We explore why speed, decentralisation, and practical integration, not hype, will define the next wave of molecular diagnostics. Jake shares how Checkt...

In this episode of Diagnosing Dx, I’m joined by Zivjena Vucetic , Chief Medical Officer at Mission Bio , to explore what it really takes to turn breakthrough diagnostics science into tools that change clinical decisions. With nearly two decades across oncology, neurology, infectious disease, and single-cell technologies, Zivjena shares a rare perspective on the messy middle of diagnostics, where g...

In this episode of Diagnosing Dx, I’m joined by Unika Alexander, Co-Founder and CEO of The Proficient Lab, to unpack what’s really happening inside today’s diagnostic labs and why many are under more pressure than ever. This conversation goes beyond hype to look at the operational reality of diagnostics — from compliance and reimbursement challenges to why modern labs need better data visibility t...

In this episode of Diagnosing Dx, I’m joined by Rachel Zayas, CEO of AGED Diagnostics, a company tackling one of the most underdiagnosed and overlooked conditions in healthcare: liver disease. Rachel shares what it really takes to build a diagnostics company from scratch in a high-friction clinical space, why liver disease is so difficult to detect early, and how systemic gaps in specialist access...

In this episode of Diagnosing Dx, I’m joined by Harald Steltzer , CEO of OrisDX , a company tackling one of the most overlooked gaps in diagnostics: early detection of head and neck cancer. Harald shares his journey from biochemistry and genetics into startup leadership, and why dentistry may be one of the most overlooked frontlines for early cancer detection today. We explore how OrisDX is rethin...

In this episode of Diagnosing Dx, I sit down with Frédéric D. Sweeney, President & CEO of VedaBio, the company pioneering a completely new class of molecular diagnostics — one that detects DNA and RNA without amplification while maintaining full clinical sensitivity in under 10 minutes. We explore how this platform could transform urgent care, decentralised testing, and infectious disease work...

In this episode, Dr. Russ Lebovitz, CEO of Amprion, explains why detecting misfolded proteins years before symptoms begin could completely reshape how we diagnose Alzheimer’s, Parkinson’s, and other neurodegenerative diseases.   He breaks down how early detection unlocks new possibilities for intervention, why alpha-synucleinis such a powerful biomarker, and what it really takes to commercialise a...

In this episode of DiagnosingDx, I’m joined by Wissam Hamou, Chief Operating Officer of One Biosciences, a company bringing single-cell diagnostics out of the lab and into real clinical practice. We explore why single-cell analysis is finally ready for the clinic, how AI is unlocking insights that were previously impossible to see, and what this technology means for trials, treatment response, and...

In this episode of Diagnosing Dx, I’m joined by Mustafa Al-Adhami, CEO and founder of Astek Consulting.   We dive into how his team is building a rapid testing platform that can confirm a UTI, detect E. coli, and identify the right antibiotic within one hour - a breakthrough that has the potential to prevent sepsis and reshape frontline care.   We also explore the realities of building a diagnosti...

In this episode of Diagnosing Dx, I’m joined by Slava Akmaev, Chief AI Officer and COO at BPGbio, and one of the earliest pioneers applying AI to diagnostics and precision medicine. We discuss how AI has evolved from early scepticism in pharma to becoming the operational backbone of modern biotech, how it’s reshaping clinical trial design and diagnostic development, and what it will take to rebuil...

In this episode of Diagnosing Dx, I sit down with Jenna Anderson, CEO of KiHealth, the company behind a breakthrough diagnostic test that can detect Type 1 diabetes years before symptoms appear. We discuss how this innovation could transform preventative healthcare, why consumer empowerment is reshaping the industry, and how KiHealth is building a future where early detection becomes the norm. Tak...

In this episode of Diagnosing Dx, I’m joined by Sally Bowden and BJ Kerns, founders of P3 Consulting, who help early-stage diagnostics startups navigate the realities of funding, regulation, and leadership.   We unpack why so much innovation never makes it off the shelf, what investors expect before backing a product, and how founders can de-risk their science to survive in today’s challenging mar...

In this episode of Diagnosing Dx, I’m joined by Ben Casavant, Co-founder and CEO of Tasso, a company redefining how blood testing works. Ben shares how a PhD side project turned into a diagnostics breakthrough, with over $120 million raised and more than two million patients served. He explains how Tasso’s painless, at-home blood collection device is making healthcare more accessible, and why inno...

In this episode of Diagnosing Dx, I’m joined by Julie Ballard, founder of Carrot Clinical and Tiger Team Bio, who has helped shape leading diagnostics companies including Genomic Health, GRAIL, and Guardant Health. Julie shares her journey from clinical laboratory scientist to entrepreneur and consultant, and what she’s learned from years of helping startups navigate the complex world of lab opera...

This week on Diagnosing Dx, I’m joined by Kaylene Ready, Chief Product Officer at Juniper Genomics, a company transforming the future of IVF through whole genome embryo testing. We explore how Juniper is turning IVF from a 50/50 coin flip into a more certain path to success, empowering families with better information and outcomes. Kayleen also shares how her background in genetics and startup lea...

This week on Diagnosing Dx, I’m joined by Scott O’Brien, who helped lead GenMark from a small startup to a $1.8 billion acquisition by Roche. Scott shares how his transition from science to commercial strategy shaped GenMark’s journey, the critical role of customer experience in competing against industry giants, and what it really takes to scale a diagnostics company through both breakthroughs an...

This week on Diagnosing Dx, I’m joined by Josh Smith, founder of Bench in a Box and scientist with a background in genetics and microbiology. Josh shares the breakthrough idea that inspired his platform, the journey to patent-pending status, and the realities of building a diagnostics startup in today’s economic climate. 🔥 What You’ll Learn: • The breakthrough behind Bench in a Box and its role i...

This week on Diagnosing Dx, I’m joined by Victoria Polyanskaya, a healthcare leader with over 10 years of experience who is driving global expansion for LinusBio.   We explore how diagnostics companies can successfully scale internationally, the opportunities in emerging markets, and the hard truths leaders need to hear when looking abroad.   🔥 What You’ll Learn: • Why exposomics is shaping the n...

This week on Diagnosing Dx , I’m joined by Dean Remy, a 35-year veteran of the life sciences industry, founder, and fundraising strategist. Dean shares his unique journey from diagnostics into technology and commercial leadership, and why fractional leadership is becoming a smart, cost-effective model for today’s startups. We dive into the evolving world of fundraising, the growing gap between inv...